ImmunityBio (IBRX) Amortization of Deferred Charges (2019 - 2024)

ImmunityBio (IBRX) has reported Amortization of Deferred Charges for 6 consecutive years, with $956000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Amortization of Deferred Charges rose 45.29% year-over-year to $956000.0; the TTM figure through Mar 2026 stood at $298000.0 (down 98.32% YoY), while the FY2024 annual figure was $22.6 million, down 46.72% from the prior year.
• Amortization of Deferred Charges rose to $956000.0 in Q1 2026 per IBRX's latest filing, from -$658000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $37.6 million in Q4 2023 and bottomed at -$658000.0 in Q2 2025.
• Historically, Amortization of Deferred Charges has averaged $5.5 million across 5 years, with a median of $1.6 million in 2023.
• Annual changes were most pronounced in 2022 — Amortization of Deferred Charges surged 449.1% — and 2025, when it tumbled 111.28%.
• ImmunityBio's Amortization of Deferred Charges stood at $12.0 million in 2022, then surged by 213.36% to $37.6 million in 2023, then sank by 86.69% to $5.0 million in 2024, then plunged by 113.14% to -$658000.0 in 2025, then jumped by 245.29% to $956000.0 in 2026.
• Business Quant data shows IBRX's Amortization of Deferred Charges at $956000.0 in Q1 2026, -$658000.0 in Q2 2025, and $658000.0 in Q1 2025.